NYSE:DVA - Davita Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$69.94 -0.20 (-0.29 %)
(As of 09/26/2018 05:01 AM ET)
Previous Close$70.14
Today's Range$69.89 - $70.58
52-Week Range$52.51 - $80.71
Volume1.11 million shs
Average Volume1.48 million shs
Market Capitalization$11.67 billion
P/E Ratio21.11
Dividend YieldN/A
Beta1.11
Davita logoDaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

Receive DVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:DVA
CUSIP23918K10
Phone303-405-2100

Debt

Debt-to-Equity Ratio1.82
Current Ratio1.90
Quick Ratio1.88

Price-To-Earnings

Trailing P/E Ratio21.11
Forward P/E Ratio17.49
P/E Growth1.04

Sales & Book Value

Annual Sales$10.88 billion
Price / Sales1.07
Cash Flow$7.7111 per share
Price / Cash9.07
Book Value$26.66 per share
Price / Book2.62

Profitability

EPS (Most Recent Fiscal Year)$3.32
Net Income$663.61 million
Net Margins4.30%
Return on Equity14.49%
Return on Assets3.63%

Miscellaneous

Employees74,500
Outstanding Shares166,900,000
Market Cap$11.67 billion

Davita (NYSE:DVA) Frequently Asked Questions

What is Davita's stock symbol?

Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."

How will Davita's stock buyback program work?

Davita declared that its Board of Directors has authorized a stock repurchase program on Wednesday, October 11th 2017, which authorizes the company to buyback $1,500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company's management believes its stock is undervalued.

How were Davita's earnings last quarter?

Davita Inc (NYSE:DVA) posted its earnings results on Wednesday, August, 1st. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $0.97 by $0.08. The firm earned $2.89 billion during the quarter, compared to the consensus estimate of $2.88 billion. Davita had a return on equity of 14.49% and a net margin of 4.30%. The business's quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter last year, the business earned $0.92 earnings per share. View Davita's Earnings History.

When is Davita's next earnings date?

Davita is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Davita.

What price target have analysts set for DVA?

10 Wall Street analysts have issued 12 month price objectives for Davita's shares. Their predictions range from $60.00 to $97.00. On average, they expect Davita's share price to reach $82.7143 in the next year. This suggests a possible upside of 18.3% from the stock's current price. View Analyst Price Targets for Davita.

What is the consensus analysts' recommendation for Davita?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 4 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Davita.

Who are some of Davita's key competitors?

Who are Davita's key executives?

Davita's management team includes the folowing people:
  • Mr. Kent J. Thiry, Chairman & CEO (Age 62)
  • Joel Ackerman, Chief Financial Officer (Age 53)
  • Mr. James K. Hilger, Chief Accounting Officer (Age 56)
  • Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 50)
  • Mr. Javier J. Rodriguez, Chief Exec. Officer of DaVita Kidney Care (Age 47)

Who are Davita's major shareholders?

Davita's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.85%), OppenheimerFunds Inc. (2.44%), Bank of New York Mellon Corp (1.90%), Bank of New York Mellon Corp (1.90%), Dimensional Fund Advisors LP (1.59%) and Boston Partners (1.22%). Company insiders that own Davita stock include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway and William L Roper. View Institutional Ownership Trends for Davita.

Which institutional investors are selling Davita stock?

DVA stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, BlackRock Inc., FMR LLC, FMR LLC, Renaissance Technologies LLC, Los Angeles Capital Management & Equity Research Inc., Mackay Shields LLC and Legal & General Group Plc. Company insiders that have sold Davita company stock in the last year include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway and William L Roper. View Insider Buying and Selling for Davita.

Which institutional investors are buying Davita stock?

DVA stock was purchased by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Investec Asset Management LTD, Glenmede Trust Co. NA, Morgan Stanley, United Services Automobile Association, Worldquant Millennium Quantitative Strategies LLC, LSV Asset Management and Chou Associates Management Inc.. View Insider Buying and Selling for Davita.

How do I buy shares of Davita?

Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Davita's stock price today?

One share of DVA stock can currently be purchased for approximately $69.94.

How big of a company is Davita?

Davita has a market capitalization of $11.67 billion and generates $10.88 billion in revenue each year. The company earns $663.61 million in net income (profit) each year or $3.32 on an earnings per share basis. Davita employs 74,500 workers across the globe.

What is Davita's official website?

The official website for Davita is http://www.davita.com.

How can I contact Davita?

Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 303-405-2100 or via email at [email protected]


MarketBeat Community Rating for Davita (NYSE DVA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  362 (Vote Outperform)
Underperform Votes:  388 (Vote Underperform)
Total Votes:  750
MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/26/2018 by MarketBeat.com Staff

Featured Article: What is a stock split?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel